A comparison of emepronium bromide and flavoxate hydrochloride in the treatment of urinary incontinence.
D000328:Adult; D001555:Benzene Derivatives / Q000009:adverse effects / Q000627:therapeutic use; D002264:Carboxylic Acids / Q000009:adverse effects / Q000627:therapeutic use; D003558:Cystoscopy; D005260:Female; D005419:Flavonoids / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010880:Piperidines / Q000009:adverse effects / Q000627:therapeutic use; D000644:Quaternary Ammonium Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014159:Transducers; D014521:Urethra / Q000503:physiopathology; D001743:Urinary Bladder / Q000503:physiopathology; D014549:Urinary Incontinence / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000503:physiopathology; D014550:Urinary Incontinence, Stress / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000503:physiopathology; D014567:Urography
D001555:Benzene Derivatives; D002264:Carboxylic Acids; D005419:Flavonoids; D010880:Piperidines; D000644:Quaternary Ammonium Compounds